Lansoprazole

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Lansoprazole

Examples of brand names: Agopton [DE]

ATC code: A02BC03

Main use (for orientation): Reflux; ulcer

Documented research summary

The associated PPI investigations concern possible interference with cannabinoid urine screening tests. They establish neither a pharmacological interaction nor a safe combination; their results depend on the test method.

Uncertainties and limitations

Negative urine tests are not evidence of safety; do not extrapolate endogenous 2-AG findings to CBD or THC. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: CYP2C19 and CYP3A4; acid-suppressing drug effect.

Type of supporting material: Product information and diagnostic investigations; not a cannabinoid pharmacokinetic pair study.

Clinical interpretation: No demonstrated specific cannabinoid pair effect.

Context: A PPI study assessed only urine-test interference. PHOSPHO1/2-AG context concerns endogenous signalling pathways, not a clinical phytocannabinoid combination.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0270]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: CYP2C19 and CYP3A4; acid-suppressing drug effect.

Source: PREVACID (LANSOPRAZOLE) CAPSULE, DELAYED RELEASE PREVACID SOLUTAB (LANSOPRAZOLE) TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE [TAKEDA PHARMACEUTICALS AMERICA, INC.] – DailyMed SPL [VD_LABEL_D0270]

Source role [VD_MED_31566030]: Diagnostics, not a pharmacological interaction

Statement supported: Lansoprazole subgroup in a small PPI urine-screening study; no clinical cannabinoid combination assessment.

Source: An assessment of urine THC immunoassay in healthy volunteers receiving an oral proton-pump inhibitor. [VD_MED_31566030]

Source role [VD_MED_38572109]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: A PPI study assessed only urine-test interference. PHOSPHO1/2-AG context concerns endogenous signalling pathways, not a clinical phytocannabinoid combination.

Source: Repurposing lansoprazole to alleviate metabolic syndrome via PHOSPHO1 inhibition. [VD_MED_38572109]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Negative urine tests are not evidence of safety; do not extrapolate endogenous 2-AG findings to CBD or THC.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0270] PREVACID (LANSOPRAZOLE) CAPSULE, DELAYED RELEASE PREVACID SOLUTAB (LANSOPRAZOLE) TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE [TAKEDA PHARMACEUTICALS AMERICA, INC.] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2025

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_31566030] An assessment of urine THC immunoassay in healthy volunteers receiving an oral proton-pump inhibitor.

Original source / bibliographic reference

Authors: Vohra V, Marraffa JM, Wojcik SM, Eggleston W.

Year: 2020

Source type: Journal Article

DOI: 10.1080/15563650.2019.1662917

PMID: 31566030

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VD_MED_38572109] Repurposing lansoprazole to alleviate metabolic syndrome via PHOSPHO1 inhibition.

Original source / bibliographic reference

Authors: Wu Y, Xin J, Li X, Yang T, Liu Y, Zhao Y, Xie W, Jiang M.

Year: 2024

Source type: research-article; Journal Article

DOI: 10.1016/j.apsb.2024.01.001

PMID: 38572109

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility